To the Editor In their recent Original Investigation in JAMA Oncology, Gettinger et al1 demonstrated the inefficacy of the nivolumab plus ipilimumab treatment regimen in improving clinical outcomes of stage IV pretreated squamous non–small cell lung cancer without checkpoint inhibitor therapy. This trial provides new insights on the unfavorable role of the nivolumab plus ipilimumab treatment regimen over monotherapy in such patients. However, we have several concerns.
Zhao B, Ma W. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer. JAMA Oncol. 2022;8(4):641–642. doi:10.1001/jamaoncol.2021.7784
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.